WO2010138588A2 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Google Patents

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Download PDF

Info

Publication number
WO2010138588A2
WO2010138588A2 PCT/US2010/036198 US2010036198W WO2010138588A2 WO 2010138588 A2 WO2010138588 A2 WO 2010138588A2 US 2010036198 W US2010036198 W US 2010036198W WO 2010138588 A2 WO2010138588 A2 WO 2010138588A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyridin
pyrrolo
chlorophenyl
piperazin
Prior art date
Application number
PCT/US2010/036198
Other languages
English (en)
French (fr)
Other versions
WO2010138588A9 (en
WO2010138588A3 (en
Inventor
Milan Bruncko
Hong Ding
George Doherty
Steven Elmore
Lisa Hasvold
Laura Hexamer
Aaron R. Kunzer
Xiaohong Song
Andrew J. Souers
Gerard Sullivan
Zhi-Fu Tao
Gary T. Wang
Le Wang
Xilu Wang
Michael Wendt
Robert Mantei
Todd M. Hansen
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010138588(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to RU2011152973A priority Critical patent/RU2535347C3/ru
Priority to PL10721246.6T priority patent/PL2435432T6/pl
Priority to RS20150592A priority patent/RS54234B2/sr
Priority to CN201080023068.1A priority patent/CN102448959B/zh
Priority to KR1020197033737A priority patent/KR20190130676A/ko
Priority to EP19195104.5A priority patent/EP3656771A1/en
Priority to CN201910261444.3A priority patent/CN109897038B/zh
Priority to BRPI1014359-9A priority patent/BRPI1014359B1/pt
Priority to EP10721246.6A priority patent/EP2435432B3/en
Priority to IL299019A priority patent/IL299019A/en
Priority to KR1020187011857A priority patent/KR101920202B1/ko
Priority to BR122019016429-0A priority patent/BR122019016429B1/pt
Priority to MX2011012257A priority patent/MX339469B/es
Priority to KR1020177008201A priority patent/KR20170037683A/ko
Priority to HRP20151001TT priority patent/HRP20151001T4/hr
Priority to KR1020187032920A priority patent/KR102001418B1/ko
Priority to CR20170019A priority patent/CR20170019A/es
Priority to KR1020197020313A priority patent/KR20190086591A/ko
Priority to SI201031011T priority patent/SI2435432T2/sl
Priority to NZ595708A priority patent/NZ595708A/en
Priority to KR1020237028352A priority patent/KR20230128571A/ko
Priority to UAA201115309A priority patent/UA106079C2/uk
Priority to DK10721246.6T priority patent/DK2435432T6/da
Priority to KR1020157014221A priority patent/KR101723378B1/ko
Priority to KR1020117030916A priority patent/KR101659583B1/ko
Priority to AU2010254160A priority patent/AU2010254160C1/en
Priority to JP2012513209A priority patent/JP5747025B2/ja
Priority to MEP-2015-124A priority patent/ME02205B/me
Priority to SG2011075843A priority patent/SG175253A1/en
Priority to CA2759182A priority patent/CA2759182C/en
Priority to ES10721246.6T priority patent/ES2546294T3/es
Publication of WO2010138588A2 publication Critical patent/WO2010138588A2/en
Publication of WO2010138588A3 publication Critical patent/WO2010138588A3/en
Publication of WO2010138588A9 publication Critical patent/WO2010138588A9/en
Priority to IL215644A priority patent/IL215644A/en
Priority to ZA2011/08616A priority patent/ZA201108616B/en
Priority to HK12103892.9A priority patent/HK1163099A1/xx
Priority to PH12015500297A priority patent/PH12015500297A1/en
Priority to AU2015201117A priority patent/AU2015201117C1/en
Priority to AU2015202183A priority patent/AU2015202183C1/en
Priority to SM201500225T priority patent/SMT201500225B/xx
Priority to AU2016277708A priority patent/AU2016277708B2/en
Priority to NL300873C priority patent/NL300873I2/nl
Priority to LTPA2017015C priority patent/LTC2435432I2/lt
Priority to CY2017019C priority patent/CY2017019I1/el
Priority to NO2017023C priority patent/NO2017023I2/no
Priority to FIEP10721246.6T priority patent/FI2435432T6/fi
Priority to IL253891A priority patent/IL253891A0/en
Priority to IL26909219A priority patent/IL269092A/en
Priority to IL286036A priority patent/IL286036A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
PCT/US2010/036198 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases WO2010138588A2 (en)

Priority Applications (47)

Application Number Priority Date Filing Date Title
RU2011152973A RU2535347C3 (ru) 2009-05-26 2010-05-26 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
PL10721246.6T PL2435432T6 (pl) 2009-05-26 2010-05-26 Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
RS20150592A RS54234B2 (sr) 2009-05-26 2010-05-26 Indukujući agensi apoptoze za lečenje kancera i imunih i autoimunih oboljenja
CN201080023068.1A CN102448959B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
KR1020197033737A KR20190130676A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
EP19195104.5A EP3656771A1 (en) 2009-05-26 2010-05-26 Process for the preparation of a synthetic intermediate for apoptosis-inducing agents
CN201910261444.3A CN109897038B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
BRPI1014359-9A BRPI1014359B1 (pt) 2009-05-26 2010-05-26 composto inibidor da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo dito composto
EP10721246.6A EP2435432B3 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL299019A IL299019A (en) 2009-05-26 2010-05-26 Method for preparing 2-(1H-pyrrolo[2,3-b]pyridine-5-aloxy)-4-(4-((9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]-undec- 8-en-8-yl)methyl)piperazine-1 yl)benzoic acid
KR1020187011857A KR101920202B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
BR122019016429-0A BR122019016429B1 (pt) 2009-05-26 2010-05-26 Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos
MX2011012257A MX339469B (es) 2009-05-26 2010-05-26 Agentes inductores de apotosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes.
KR1020177008201A KR20170037683A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
HRP20151001TT HRP20151001T4 (hr) 2009-05-26 2010-05-26 Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti
KR1020187032920A KR102001418B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
CR20170019A CR20170019A (es) 2009-05-26 2010-05-26 Agentes inductores de apoptosis para eltratamiento de cáncer y enfermedades inmunes y autoinmunes
KR1020197020313A KR20190086591A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
SI201031011T SI2435432T2 (sl) 2009-05-26 2010-05-26 Sredstva, ki inducirajo apoptozo, za zdravljenje raka in imunskih in avtoimunskih bolezni
NZ595708A NZ595708A (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR1020237028352A KR20230128571A (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
UAA201115309A UA106079C2 (uk) 2009-05-26 2010-05-26 Індукуючі апоптоз засоби для лікування злоякісної пухлини і імунних і аутоімунних захворювань
DK10721246.6T DK2435432T6 (da) 2009-05-26 2010-05-26 Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
KR1020157014221A KR101723378B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
KR1020117030916A KR101659583B1 (ko) 2009-05-26 2010-05-26 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
AU2010254160A AU2010254160C1 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012513209A JP5747025B2 (ja) 2009-05-26 2010-05-26 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
MEP-2015-124A ME02205B (me) 2009-05-26 2010-05-26 INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
SG2011075843A SG175253A1 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2759182A CA2759182C (en) 2009-05-26 2010-05-26 (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES10721246.6T ES2546294T3 (es) 2009-05-26 2010-05-26 Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
IL215644A IL215644A (en) 2009-05-26 2011-10-09 N-phenylsulfonyl-2- (h1-pyrrolo [3,2- b] pyridine-5-yloxy) benzamide and anticancer drugs containing them
ZA2011/08616A ZA201108616B (en) 2009-05-26 2011-11-23 Apoptosis-inducing agents for the tratment of cancer and immune and autoimmune diseases
HK12103892.9A HK1163099A1 (en) 2009-05-26 2012-04-19 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12015500297A PH12015500297A1 (en) 2009-05-26 2015-02-10 Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
AU2015201117A AU2015201117C1 (en) 2009-05-26 2015-03-04 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2015202183A AU2015202183C1 (en) 2009-05-26 2015-04-29 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SM201500225T SMT201500225B (it) 2009-05-26 2015-09-24 Agenti induttori di apaptosi per il trattamento del cancro e delle malattie immuni e autoimmuni
AU2016277708A AU2016277708B2 (en) 2009-05-26 2016-12-23 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NL300873C NL300873I2 (nl) 2009-05-26 2017-05-16 Venetoclax
LTPA2017015C LTC2435432I2 (lt) 2009-05-26 2017-05-18 Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
CY2017019C CY2017019I1 (el) 2009-05-26 2017-05-25 Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
NO2017023C NO2017023I2 (no) 2009-05-26 2017-05-29 Venetoklaks
FIEP10721246.6T FI2435432T6 (fi) 2009-05-26 2017-05-29 Apoptoosia indusoivia aineita syövän ja immuuni- ja autoimmuunitautien hoitoa varten
IL253891A IL253891A0 (en) 2009-05-26 2017-08-07 Apoptosis promoting substances for the treatment of cancer, immune diseases and immunodeficiency diseases
IL26909219A IL269092A (en) 2009-05-26 2019-09-03 Process for preparing 2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine-1-yl )-N-({4-[(1-methylpiperidin-4-yl)amino]3-nitrophenyl}sulfonyl)benzamide
IL286036A IL286036A (en) 2009-05-26 2021-09-01 Method for preparing 2-(1h-pyrrolo[2,3-b]pyridine-5-aloxy)-4-(4-((9-(4-chlorophenyl)-3-(1,3-difluoropropane-2-yl) -3-Azaspiro[5.5]-undec-8-en-8-yl)methyl)piperazine-1-yl)benzoic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26
US61/181,203 2009-05-26

Publications (3)

Publication Number Publication Date
WO2010138588A2 true WO2010138588A2 (en) 2010-12-02
WO2010138588A3 WO2010138588A3 (en) 2011-04-07
WO2010138588A9 WO2010138588A9 (en) 2011-05-05

Family

ID=42677657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/036198 WO2010138588A2 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Country Status (43)

Country Link
US (1) US8580794B2 (en17)
EP (3) EP2435432B3 (en17)
JP (7) JP5747025B2 (en17)
KR (8) KR101659583B1 (en17)
CN (5) CN109966294A (en17)
AR (2) AR076705A1 (en17)
AU (1) AU2010254160C1 (en17)
BR (2) BR122019016429B1 (en17)
CA (4) CA3052016A1 (en17)
CL (1) CL2011002949A1 (en17)
CO (1) CO6480950A2 (en17)
CR (2) CR20170019A (en17)
CY (2) CY1117423T1 (en17)
DK (1) DK2435432T6 (en17)
DO (1) DOP2011000367A (en17)
EC (1) ECSP11011554A (en17)
ES (1) ES2546294T3 (en17)
FI (1) FI2435432T6 (en17)
HK (2) HK1163099A1 (en17)
HR (1) HRP20151001T4 (en17)
HU (2) HUE027698T2 (en17)
IL (5) IL299019A (en17)
LT (1) LTC2435432I2 (en17)
ME (1) ME02205B (en17)
MX (2) MX339469B (en17)
MY (1) MY155645A (en17)
NL (1) NL300873I2 (en17)
NO (1) NO2017023I2 (en17)
NZ (1) NZ595708A (en17)
PE (1) PE20120345A1 (en17)
PH (1) PH12015500297A1 (en17)
PL (1) PL2435432T6 (en17)
PT (1) PT2435432E (en17)
RS (1) RS54234B2 (en17)
RU (3) RU2535347C3 (en17)
SG (2) SG10201704742YA (en17)
SI (1) SI2435432T2 (en17)
SM (1) SMT201500225B (en17)
TW (3) TWI537269B (en17)
UA (1) UA106079C2 (en17)
UY (3) UY32668A (en17)
WO (1) WO2010138588A2 (en17)
ZA (1) ZA201108616B (en17)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110103406A (ko) * 2008-12-05 2011-09-20 아보트 러보러터리즈 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
WO2011149492A1 (en) * 2010-05-26 2011-12-01 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
WO2012071336A1 (en) * 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
WO2012111839A1 (en) 2011-02-15 2012-08-23 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
WO2012121758A1 (en) * 2010-10-29 2012-09-13 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US8580794B2 (en) 2009-05-26 2013-11-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
WO2014175317A1 (ja) 2013-04-24 2014-10-30 第一三共株式会社 ジカルボン酸化合物
US8952157B2 (en) 2008-12-04 2015-02-10 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2011258350B2 (en) * 2010-05-26 2015-04-09 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9018381B2 (en) 2010-08-06 2015-04-28 Astrazeneca Ab Chemical compounds
US9029404B2 (en) 2008-12-04 2015-05-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9072748B2 (en) 2008-12-05 2015-07-07 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
JP2015529193A (ja) * 2012-08-13 2015-10-05 アッヴィ・インコーポレイテッド アポトーシス誘発剤
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017157813A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US9782408B2 (en) 2014-10-06 2017-10-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US9877958B2 (en) 2011-10-14 2018-01-30 Abbvie Inc. Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10314920B2 (en) 2017-02-22 2019-06-11 Astrazeneca Ab Therapeutic dendrimers
WO2019144117A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
WO2019161221A2 (en) 2018-02-16 2019-08-22 Abbvie Inc. Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
WO2020026100A1 (en) 2018-07-30 2020-02-06 Astrazeneca Ab Combination therapy for treating cancer
WO2020024826A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020088442A1 (zh) 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10758524B2 (en) 2014-07-22 2020-09-01 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2020238785A1 (zh) 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
US10898570B2 (en) 2015-07-07 2021-01-26 Genentech, Inc. Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
WO2021219065A1 (zh) 2020-04-29 2021-11-04 正大天晴药业集团股份有限公司 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2022037683A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US11279711B2 (en) 2017-08-23 2022-03-22 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11318134B2 (en) 2018-01-10 2022-05-03 Recurium Ip Holdings, Llc Benzamide compounds
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
US11478470B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
RU2782469C2 (ru) * 2017-04-18 2022-10-27 Шанхай Фокон Фармасьютикал Ко., Лтд. Апоптоз-индуцирующие агенты
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2022253313A1 (zh) 2021-06-04 2022-12-08 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
RU2539587C2 (ru) * 2009-01-19 2015-01-20 Эббви Инк. Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
IL300955A (en) 2010-06-03 2023-04-01 Pharmacyclics Llc (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
ES2691742T5 (es) * 2012-11-01 2022-03-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
US9006438B2 (en) 2013-03-13 2015-04-14 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
CA2950640A1 (en) 2015-12-04 2017-06-04 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
JP7374496B2 (ja) 2017-06-26 2023-11-07 深▲チェン▼市塔吉瑞生物医薬有限公司 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
EP3788035A2 (en) 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
CN112661751A (zh) * 2019-10-16 2021-04-16 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114929689A (zh) * 2019-10-28 2022-08-19 百济神州有限公司 Bcl-2抑制剂
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114478520A (zh) * 2020-10-28 2022-05-13 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CA3211639A1 (en) * 2021-03-19 2022-09-22 Volodymyr KYSIL Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
TW202328125A (zh) * 2021-08-31 2023-07-16 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑的固體形式、製備方法及其用途
WO2024017354A1 (en) * 2022-07-21 2024-01-25 Beigene, Ltd. Methods of treating multiple myeloma using bcl-2 inhibitor
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
CZ141795A3 (en) * 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
WO1999018099A1 (en) * 1997-10-03 1999-04-15 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
MXPA02006474A (es) 1999-12-28 2002-11-29 Eisai Co Ltd Compuestos heterociclicos que contienen sulfonamida.
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60213810T2 (de) 2001-06-06 2007-02-01 Eli Lilly And Co., Indianapolis Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
BRPI0511070A (pt) * 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
US20080300267A1 (en) 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
EP2061560A2 (en) * 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2011005922A (es) 2008-12-05 2011-06-16 Abbott Lab Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes.
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
RU2539587C2 (ru) * 2009-01-19 2015-01-20 Эббви Инк. Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
TWI537269B (zh) * 2009-05-26 2016-06-11 艾伯維巴哈馬有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry", PURE APPL. CHEM., vol. 45, 1976, pages 13 - 10
BLAKE ET AL., J. PHARM. SCI., vol. 64, no. 3, 1975, pages 367 - 391
BLOOD, vol. 111, 2008, pages 2300 - 2309
BLOOD, vol. 95, no. 4, 2000, pages 1283 - 92
BRICKNER, S J ET AL., J MED CHEM, vol. 39, no. 3, 1996, pages 673
BRITISH JOURNAL OF HAEMATOLOGY, vol. 110, no. 3, 2000, pages 584 - 90
C. D. JONES; M. KASELJ; R. N. SALVATORE; W. J. LE NOBLE, J. ORG. CHEM., vol. 63, 1998, pages 2758 - 2760
CURRENT ALLERGY AND ASTHMA REPORTS, vol. 3, 2003, pages 378 - 384
CZAJKA D M; FINKEL A J, ANN. N.Y. ACAD. SCI., vol. 84, 1960, pages 770
CZAKJA D M ET AL., AM. J. PHYSIOL., vol. 201, 1961, pages 357
DIABETES METAB., vol. 23, 1997, pages 251
KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., vol. 36, no. 10, 1995, pages 927 - 932
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88
LIZONDO, J ET AL., DRUGS FUT, vol. 21, no. 11, 1996, pages 1116
MALLESHAM, B ET AL., ORG LETT, vol. 5, no. 7, 2003, pages 963
NEW ENGLAND JOURNAL OF MEDICINE, vol. 351, no. 14, 2004, pages 1409 - 1418
THOMSON J F, ANN. NEW YORK ACAD. SCI, vol. 84, 1960, pages 736
TSE, CANCER RESEARCH, vol. 68, no. 9, 2008, pages 3421
V.R. SUTTON; D.L. VAUX; J.A. TRAPANI, J. OF IMMUNOLOGY, vol. 158, no. 12, 1997, pages 5783
WANG Z.-X.: "An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule", FEBS LETT., vol. 360, 1995, pages 111 - 4
WANG ZX: "An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule", FEBS LETT., vol. 360, 1995, pages 111 - 4

Cited By (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303025B2 (en) 2008-12-04 2016-04-05 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8952157B2 (en) 2008-12-04 2015-02-10 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9029404B2 (en) 2008-12-04 2015-05-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20110103406A (ko) * 2008-12-05 2011-09-20 아보트 러보러터리즈 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
KR101692705B1 (ko) 2008-12-05 2017-01-04 애브비 인코포레이티드 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
EP2376480B1 (en) * 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9315488B2 (en) 2008-12-05 2016-04-19 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9072748B2 (en) 2008-12-05 2015-07-07 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
KR101787993B1 (ko) 2008-12-05 2017-10-19 애브비 인코포레이티드 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
JP2020023545A (ja) * 2009-05-26 2020-02-13 アッヴィ・アイルランド・アンリミテッド・カンパニー 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9174982B2 (en) 2009-05-26 2015-11-03 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9045475B2 (en) 2009-05-26 2015-06-02 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580794B2 (en) 2009-05-26 2013-11-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011149492A1 (en) * 2010-05-26 2011-12-01 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9403822B2 (en) 2010-05-26 2016-08-02 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9006247B2 (en) 2010-05-26 2015-04-14 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2011258350B2 (en) * 2010-05-26 2015-04-09 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2010354083B2 (en) * 2010-05-26 2015-02-12 Abbvie Ireland Unlimited Company Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101850679B1 (ko) 2010-05-26 2018-04-20 애브비 인코포레이티드 암과 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스―유도제
KR101800167B1 (ko) 2010-05-26 2017-11-22 애브비 인코포레이티드 암과 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스―유도제
US9018381B2 (en) 2010-08-06 2015-04-28 Astrazeneca Ab Chemical compounds
US9248140B2 (en) 2010-08-06 2016-02-02 Astrazeneca Ab Chemical compounds
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
WO2012121758A1 (en) * 2010-10-29 2012-09-13 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
EP3219308A1 (en) * 2010-10-29 2017-09-20 AbbVie Ireland Unlimited Company Melt-extruded solid dispersions containing an apoptosis-inducing agent
EP4218731A3 (en) * 2010-10-29 2023-08-16 AbbVie Ireland Unlimited Company Melt-extruded solid dispersions containing an apoptosis-inducing agent
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
US10730873B2 (en) 2010-11-23 2020-08-04 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
EP3028702A1 (en) 2010-11-23 2016-06-08 AbbVie Bahamas Limited Methods of treatment using selective bcl-2 inhibitors
WO2012071336A1 (en) * 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
EP2643322B1 (en) 2010-11-23 2017-08-30 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
JP2013543894A (ja) * 2010-11-23 2013-12-09 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
US9840502B2 (en) 2010-11-23 2017-12-12 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
WO2012111839A1 (en) 2011-02-15 2012-08-23 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
US9877958B2 (en) 2011-10-14 2018-01-30 Abbvie Inc. Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
EP2882439A4 (en) * 2012-08-13 2015-12-23 Abbvie Inc inducers of apoptosis
JP2015529193A (ja) * 2012-08-13 2015-10-05 アッヴィ・インコーポレイテッド アポトーシス誘発剤
US11413282B2 (en) 2012-09-07 2022-08-16 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
US11110087B2 (en) 2012-09-07 2021-09-07 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
US10993942B2 (en) 2012-09-07 2021-05-04 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
EP3919079A1 (en) 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
US11590128B2 (en) 2012-09-07 2023-02-28 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014175317A1 (ja) 2013-04-24 2014-10-30 第一三共株式会社 ジカルボン酸化合物
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
US10758524B2 (en) 2014-07-22 2020-09-01 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
US10258624B2 (en) 2014-10-06 2019-04-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10758534B2 (en) 2014-10-06 2020-09-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US9782408B2 (en) 2014-10-06 2017-10-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10426788B2 (en) 2015-03-13 2019-10-01 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10898570B2 (en) 2015-07-07 2021-01-26 Genentech, Inc. Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
US11013698B2 (en) 2016-03-15 2021-05-25 Oryzon Genomics S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US10265279B2 (en) 2016-03-15 2019-04-23 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017157813A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US11319316B2 (en) 2016-04-21 2022-05-03 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
US11718613B2 (en) 2016-08-05 2023-08-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11186566B2 (en) 2016-09-30 2021-11-30 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
EP3565815A4 (en) * 2017-01-07 2020-10-28 Shanghai Fochon Pharmaceutical Co., Ltd. COMPOUNDS AS BCL-2 SELECTIVE APOPTOSIS INDUCING AGENTS
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
US10888624B2 (en) 2017-02-22 2021-01-12 Astrazeneca Ab Therapeutic dendrimers
US10314920B2 (en) 2017-02-22 2019-06-11 Astrazeneca Ab Therapeutic dendrimers
US11717574B2 (en) 2017-02-22 2023-08-08 Astrazeneca Ab Therapeutic dendrimers
TWI791511B (zh) * 2017-04-18 2023-02-11 大陸商重慶複創醫藥研究有限公司 細胞凋亡誘導劑
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
EP4119560A1 (en) * 2017-04-18 2023-01-18 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
US11091478B2 (en) * 2017-04-18 2021-08-17 Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
KR102630069B1 (ko) 2017-04-18 2024-01-26 포천 파마슈티컬즈, 엘티디. 아폽토시스-유도제
KR20190140910A (ko) * 2017-04-18 2019-12-20 상하이 포천 파마슈티컬 씨오 엘티디 아폽토시스-유도제
RU2782469C2 (ru) * 2017-04-18 2022-10-27 Шанхай Фокон Фармасьютикал Ко., Лтд. Апоптоз-индуцирующие агенты
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11680072B2 (en) 2017-08-23 2023-06-20 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11365206B2 (en) 2017-08-23 2022-06-21 Newave Pharmaceutical Inc. BCL-2 inhibitors
US11279711B2 (en) 2017-08-23 2022-03-22 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11318134B2 (en) 2018-01-10 2022-05-03 Recurium Ip Holdings, Llc Benzamide compounds
US11344546B2 (en) 2018-01-10 2022-05-31 Recurium IP Holding, LLC Benzamide compounds
US11813259B2 (en) 2018-01-10 2023-11-14 Recurium Ip Holdings, Llc Benzamide compounds
US11590126B2 (en) 2018-01-10 2023-02-28 Recurium Ip Holdings, Llc Benzamide compounds
US11813260B1 (en) 2018-01-10 2023-11-14 Recurium Ip Holdings, Llc Benzamide compounds
WO2019144117A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
WO2019161221A2 (en) 2018-02-16 2019-08-22 Abbvie Inc. Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
WO2020026100A1 (en) 2018-07-30 2020-02-06 Astrazeneca Ab Combination therapy for treating cancer
US11478470B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
WO2020024826A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020088442A1 (zh) 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
AU2019372640B2 (en) * 2018-10-29 2022-08-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor
US20220002290A1 (en) * 2018-10-29 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
EP3858832A4 (en) * 2018-10-29 2022-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2 SELECTIVE INHIBITOR
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
EP3978494A4 (en) * 2019-05-24 2023-04-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS
WO2020238785A1 (zh) 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
WO2021219065A1 (zh) 2020-04-29 2021-11-04 正大天晴药业集团股份有限公司 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体
EP4129998A4 (en) * 2020-04-29 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd CRYSTAL OF A TRIFLUOROMETHYL/CHLORODISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR
WO2022037683A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2022253313A1 (zh) 2021-06-04 2022-12-08 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications

Also Published As

Publication number Publication date
KR102001418B1 (ko) 2019-07-19
PT2435432E (pt) 2015-10-13
PL2435432T6 (pl) 2024-02-12
CN102448959B (zh) 2015-06-17
CA2759182A1 (en) 2010-12-02
RU2015154494A (ru) 2017-06-22
EP2435432A2 (en) 2012-04-04
KR20230128571A (ko) 2023-09-05
NL300873I2 (nl) 2017-10-24
EP2944638A1 (en) 2015-11-18
MX2019012154A (es) 2019-11-21
CO6480950A2 (es) 2012-07-16
CN109966294A (zh) 2019-07-05
EP2435432B1 (en) 2015-06-24
AR109974A2 (es) 2019-02-13
DK2435432T3 (en) 2015-08-31
CN109897038A (zh) 2019-06-18
CN109897038B (zh) 2022-04-05
TWI561523B (en) 2016-12-11
RU2014132884A (ru) 2015-12-27
WO2010138588A9 (en) 2011-05-05
RU2628885C2 (ru) 2017-08-22
UY33047A (es) 2011-09-30
KR20180049164A (ko) 2018-05-10
RU2573832C2 (ru) 2016-01-27
CN104906100A (zh) 2015-09-16
TWI537269B (zh) 2016-06-11
HK1215576A1 (zh) 2016-09-02
SI2435432T1 (sl) 2015-10-30
JP2015110605A (ja) 2015-06-18
RU2535347C3 (ru) 2019-05-14
ES2546294T3 (es) 2015-09-22
JP5747025B2 (ja) 2015-07-08
HUS1700021I1 (hu) 2017-06-28
JP6353506B2 (ja) 2018-07-04
SG175253A1 (en) 2011-11-28
KR20190086591A (ko) 2019-07-22
JP2020023545A (ja) 2020-02-13
KR20170037683A (ko) 2017-04-04
FI2435432T6 (fi) 2023-11-21
TW201107323A (en) 2011-03-01
TW201607946A (zh) 2016-03-01
MX2011012257A (es) 2011-12-16
KR20180124164A (ko) 2018-11-20
RU2535347C2 (ru) 2014-12-10
PE20120345A1 (es) 2012-05-17
BRPI1014359B1 (pt) 2019-11-05
SI2435432T2 (sl) 2024-04-30
UA106079C2 (uk) 2014-07-25
MX339469B (es) 2016-05-27
AU2010254160A1 (en) 2011-11-24
JP2017048219A (ja) 2017-03-09
AU2010254160C1 (en) 2023-07-06
CY1117423T1 (el) 2017-04-26
DOP2011000367A (es) 2017-07-31
JP6038195B2 (ja) 2016-12-07
KR20190130676A (ko) 2019-11-22
IL253891A0 (en) 2017-10-31
CN104876927B (zh) 2017-06-23
CY2017019I2 (el) 2018-01-10
NO2017023I1 (no) 2017-05-29
JP2012528178A (ja) 2012-11-12
HRP20151001T4 (hr) 2024-02-16
BRPI1014359A2 (pt) 2016-04-05
KR101920202B1 (ko) 2018-11-21
IL299019A (en) 2023-02-01
LTC2435432I2 (lt) 2018-06-11
NZ595708A (en) 2014-03-28
CA2759182C (en) 2016-06-07
SG10201704742YA (en) 2017-07-28
CN102448959A (zh) 2012-05-09
HRP20151001T1 (hr) 2015-10-23
KR20120034671A (ko) 2012-04-12
JP2018138577A (ja) 2018-09-06
IL286036A (en) 2021-10-31
RU2011152973A (ru) 2013-07-10
PL2435432T3 (pl) 2015-12-31
NO2017023I2 (no) 2017-05-29
DK2435432T6 (da) 2023-12-18
UY37825A (es) 2020-02-28
RS54234B2 (sr) 2024-02-29
CN104876927A (zh) 2015-09-02
LTPA2017015I1 (lt) 2017-06-12
KR101659583B1 (ko) 2016-09-29
IL269092A (en) 2019-11-28
HK1163099A1 (en) 2012-09-07
TW201506025A (zh) 2015-02-16
EP3656771A1 (en) 2020-05-27
JP2022033939A (ja) 2022-03-02
UY32668A (es) 2010-12-31
CR20110632A (es) 2012-02-15
US20110124628A1 (en) 2011-05-26
RS54234B1 (en) 2015-12-31
MY155645A (en) 2015-11-13
CR20170019A (es) 2017-05-12
TWI476195B (zh) 2015-03-11
CL2011002949A1 (es) 2012-05-25
PH12015500297A1 (en) 2015-12-07
IL215644A0 (en) 2012-01-31
JP2023040165A (ja) 2023-03-22
ECSP11011554A (es) 2012-01-31
IL215644A (en) 2017-08-31
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
SMT201500225B (it) 2015-10-30
WO2010138588A3 (en) 2011-04-07
CA3206963A1 (en) 2010-12-02
ME02205B (me) 2016-02-20
HUE027698T2 (en) 2016-10-28
US8580794B2 (en) 2013-11-12
ZA201108616B (en) 2015-12-23
CA2929347A1 (en) 2010-12-02
AR076705A1 (es) 2011-06-29
KR20150065947A (ko) 2015-06-15
CA3052016A1 (en) 2010-12-02
EP2435432B3 (en) 2023-10-25
KR101723378B1 (ko) 2017-04-06
BR122019016429B1 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
RU2628885C2 (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
US9174982B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2016277708B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080023068.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10721246

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 215644

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 595708

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 8004/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2759182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/012257

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010254160

Country of ref document: AU

Date of ref document: 20100526

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012513209

Country of ref document: JP

Ref document number: 002025-2011

Country of ref document: PE

Ref document number: CR2011-000632

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010721246

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117030916

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201115309

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2011152973

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11178424

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1014359

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 12015500297

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P-2015/0592

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI1014359

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111024

WWE Wipo information: entry into national phase

Ref document number: IDP00201605760

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 201719

Country of ref document: CR

Ref document number: CR2017-000019

Country of ref document: CR